Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

Effect of Thalidomide, Carmofur and Compound Mylabris Capsules (TCC) Cocktail Combined With Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone on Survival in Patients With Unresectable Hepatocellular Carcinoma

This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).

Inclusion Criteria:

• patients who met the HCC diagnostic criteria according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China.
• patients underwent conventional TACE.
• availability of complete medical records for data extraction and follow-up.

Exclusion Criteria:

• a history of previous or synchronous treatment for tumors such as radio frequency ablation (RFA) or systemic chemotherapy.
• poor liver functions (Child-Pugh class C).
• accompanying other life-threatening diseases.